Grand Round Webinar: Vaccination and infectious disease

February 27, 2026|1:00 PM UK time|Past event

Britain lost its measles elimination status in January 2026 after years of progress, as 130 fresh cases hit England by mid-February—mostly unvaccinated London schoolchildren—and a new combined vaccine schedule takes effect.

Key takeaways

  • The UK forfeited WHO measles elimination status in January 2026 after 2,911 confirmed cases in England in 2024 and 959 in 2025, with pertussis claiming 11 infant lives that same year amid nearly 15,000 notifications.
  • Ongoing 2026 outbreaks, 88 of 130 cases in London, have hospitalised children and disrupted schools while national childhood immunisation rates sit at decade lows and below the 95% herd-immunity threshold across G7 nations.
  • The January 2026 switch to MMRV vaccine plus an 18-month second dose aims to deliver earlier protection against four diseases and save the NHS £15 million yearly on chickenpox treatment while cutting £24 million in lost productivity, yet low uptake in deprived areas reveals persistent access and trust barriers.

Measles Resurgence Exposed

The United Kingdom has surrendered its measles-free status. The World Health Organisation declared the disease re-established in January 2026 after England recorded 2,911 laboratory-confirmed cases in 2024, the highest annual total in more than a decade. By 16 February 2026 another 130 cases had been confirmed nationwide, two-thirds in London, with clusters centred on schools and nurseries.

Unvaccinated children under 10 bear the brunt. Several have been admitted to hospital with complications that range from pneumonia to encephalitis; one preventable death occurred in a 2024 outbreak. The pattern repeats the pertussis surge of that year, which produced nearly 15,000 notifications and 11 infant fatalities, signalling broader erosion of vaccine confidence.

Economic stakes are concrete. Chickenpox alone costs the UK economy an estimated £24 million annually in lost parental earnings and productivity; the new MMRV programme is projected to save the NHS £15 million a year in direct treatment costs. Yet coverage for routine jabs, including MMR, remains the lowest in the G7 and well below the 95 per cent needed for herd protection.

From 1 January 2026 the schedule introduced the combined measles-mumps-rubella-varicella vaccine and moved the second dose forward to 18 months for eligible children. Countries such as Australia, Canada and Germany have used the formulation safely for over a decade. The change is designed to lock in immunity earlier, when vulnerability peaks, and to simplify delivery in hopes of lifting overall uptake.

Non-obvious tensions complicate the picture. Uptake collapses in high-deprivation boroughs and certain communities where booking systems, transport and continuity of care are weakest. Lingering misinformation from the pandemic era collides with logistical strain: the extra 18-month appointment adds pressure on already stretched primary care while catch-up drives compete for attention. Equity gaps that once seemed marginal now determine whether outbreaks remain containable or become entrenched.

We use cookies to measure site usage. Privacy Policy